Vitrolife Group (VITR) Q1 2026 earnings summary

Executive summary

• Organic sales growth of 5% in local currencies, with net sales at SEK 807 million, though reported sales declined 4% in SEK due to currency effects.

• Gross margin reached 59.9%, one of the highest in recent quarters, up 2.5 percentage points year-over-year, driven by favorable product and market mix.

• EBITDA margin improved to 31.1%, with net income stable at SEK 101 million and EPS at SEK 0.74.

• Strong performance in North America and APAC, offset by significant declines in the Middle East due to geopolitical instability.

• Strategic focus on profitable growth, innovation, and operational excellence, including ongoing restructuring and cost optimization.

Financial highlights

• Net sales: SEK 807 million, 5% organic growth in local currencies, but -4% reported due to 9% negative currency impact.

• Gross income: SEK 483 million, gross margin 59.9% (up from 57.4%), driven by strong sales in Consumables and Technologies.

• EBITDA: SEK 251 million, margin 31.1% (up from 30.6%).

• Net income: SEK 101 million; EPS: SEK 0.74.

• Cash flow from operating activities: SEK 172 million, up from SEK 69 million last year.

• Net debt/EBITDA: 0.6, improved from 0.7 year-over-year.

• Proposed dividend: SEK 1.10 per share.

Outlook and guidance

• Expectation of continued strong performance in North America, with potential for further acceleration in Q3 due to favorable comps.

• APAC outlook is cautiously optimistic, with signs of recovery but requiring sustained quarters of growth.

• Gross margin expected to remain strong, supported by ongoing focus on profitable segments and geographies.

• Restructuring savings to have greater impact from Q2 onwards, with full impact by end of Q3 2026.

• Continued investment in IT, digital capabilities, and R&D to support growth and innovation.